![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
Vol. 20, Issue 3, 745-756, February 1, 2009
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vβ3 Integrin Expression and Proteolytic Processing of Urokinase-type Plasminogen Activator Receptor
*Department of Molecular Immunology, Center for Physiology, Pathophysiology and Immunology, Medical University of Vienna, A-1090 Vienna, Austria; Department of Vascular Biology and Thrombosis Research, Center for Biomolecular Medicine, Medical University of Vienna, A-1090 Vienna, Austria; and Institute of Molecular Biology, Slovak Academy of Sciences, 845 51 Bratislava, Slovak Republic
Submitted June 6, 2008;
Revised October 27, 2008;
Accepted November 18, 2008
Monitoring Editor: M. Bishr Omary
 |
ABSTRACT |
|---|
 TOP ABSTRACT INTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
V integrins. Genetic rescue experiments and inhibitor studies revealed that the enhanced plasminogen activation was due to a direct effect of M6P/IGF2R on uPAR, whereas increased cell adhesion to vitronectin was dependent on V integrin expression and not uPAR. Increased cell invasion of M6P/IGF2R knockdown cells was rescued by cosilencing both uPAR and V integrin. Furthermore, we found that M6P/IGF2R expression accelerates the cleavage of uPAR. M6P/IGF2R silencing resulted in an increased ratio of full-length uPAR to the truncated D2D3 fragment, incapable of binding most uPAR ligands. We conclude that M6P/IGF2R controls cell invasion by regulating V integrin expression and by accelerating uPAR cleavage, leading to the loss of the urokinase/vitronectin/integrin-binding site on uPAR. |
INTRODUCTION |
|---|
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
; Hebert, 2006). M6P/IGF2R is a multifunctional receptor possessing distinct binding sites for structurally unrelated ligands and membrane partners (Ghosh et al., 2003). It is not clear, however, what functional consequence of the loss of M6P/IGF2R is directly and determinedly responsible for tumor progression in vivo. First, the M6P/IGF2R-mediated degradation of insulin-like growth factor (IGF) 2 may play a role in suppression of tumor growth (Samani et al., 2007). Second, the lack of M6P/IGF2R in tumor cells may also contribute to their higher invasiveness due to impaired intracellular trafficking of cathepsins (Lorenzo et al., 2000), observed also in M6P/IGF2R-deficient cell lines (Kasper et al., 1996). Third, some of the M6P/IGF2R's ligands, such as retinoic acid and granzyme B, were shown to induce apoptosis via the receptor (Kang et al., 1997; Motyka et al., 2000). Fourth, the loss of M6P/IGF2R may reduce the availability of active transforming growth factor (TGF)-β and thus its inhibitory effects on cell proliferation (Dennis and Rifkin, 1991; Godar et al., 1999; Leksa et al., 2005). Finally, M6P/IGF2R binds the urokinase-type plasminogen activator receptor (uPAR, CD87) and plasminogen (Plg), two components of the fibrinolytic system (Nykjaer et al., 1998; Godar et al., 1999; Leksa et al., 2002; Kreiling et al., 2003). Plg activation is crucial to direct cell migration through tissue barriers. On binding to uPAR, pro-urokinase (pro-uPA) is proteolytically activated to urokinase-type plasminogen activator (uPA), and in turn uPA specifically activates cell-bound Plg to the serine protease plasmin. Plasmin facilitates cell migration through degradation of extracellular matrix components both directly and through the activation of matrix metalloproteinases (Ragno, 2006). Virtually all types of cancer engage the fibrinolytic system during tumor progression (Dano et al., 2005). Accordingly, the cell-associated activity and expression of uPA and uPAR strongly correlate with bad prognosis in most cancers (Dass et al., 2008). Furthermore, the fibrinolytic system on endothelial cells is needed for angiogenesis and is hijacked by tumors for vessel growth (Mazar et al., 1999).
In this study, we addressed the question which of the above-mentioned molecular interactions of M6P/IGF2R might be involved in regulating cell invasion. Using RNA interference with M6P/IGF2R in human cancer and endothelial cell lines, we show that M6P/IGF2R interacts with full-length uPAR and accelerates the proteolytic cleavage of uPAR, thereby interfering with the Plg activation cascade and thus cell invasion. Furthermore, the M6P/IGF2R knockdown cells up-regulate Vβ3 integrin expression, which has been associated with enhanced cell motility and invasion (Felding-Habermann et al., 2001). Therefore, control over the proteolytic capacity and Vβ3 integrin expression of cells feature a tumor-suppressive role for M6P/IGF2R to hinder the metastatic progression of cancer.
|
MATERIALS AND METHODS |
|---|
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
2-antiplasmin, human epidermal growth factor (EGF), and tranexamic acid (TA) were from Sigma-Aldrich (Vienna, Austria). Nonidet P-40 and EZ-Link Sulfo-NHS-biotin were from Pierce Chemical (Rockford, IL). Plasmin and uPA-specific substrates S-2251 and S-2444 were from CoaChrom Diagnostica (Vienna, Austria). Bovine serum albumin (BSA) was a product of Behring (Marburg, Germany). Streptavidin-Sepharose high performance was from GE Healthcare (Uppsala, Sweden).
Antibodies
The monoclonal antibodies (mAbs) MEM-238 and MEM-240 to M6P/IGF2R and MEM-101A to β1 integrin were from Dr. Václav H
rej
í (Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Prague, Czech Republic); the mAbs H2 and C8 to uPAR were provided by Dr. Ulrich Weidle (Roche Diagnostics, Division Pharma, Penzberg, Germany). The rabbit polyclonal antibody (Ab) Ab32815 to M6P/IGF2R and the anti-uPAR Ab Ab27423 were both from Abcam (Cambridge, United Kingdom). The mAbs 3931, 3932, and 3936 to uPAR were from American Diagnostica (Stamford, CT). The mAb MAB1953, the Alexa Fluor 488-conjugated MAB1976X, both to Vβ3 integrin; the mAb CBL536 to 4 integrin; the mAb AB1928 to 5 integrin; and the mAb CBL458 to 6 integrin were all from Millipore Bioscience Research Reagents (Temecula, CA). The mAb MA-49A0 to 1 integrin was from Endogen (Woburn, MA). Antibodies against pro-uPA/uPA (35scuPA and 8scuPA) were from Technoclone. Neutralizing antibodies against TGFβ isoforms (anti-TGFβ1 [AF-101-NA], anti-TGFβ2 [AB-112-NA], and anti-TGFβ3 [AB-244-NA]) were from R&D Systems (Minneapolis, MN); the IGF2 neutralizing antibody S1F2 was from Millipore (Lake Placid, NY).
Cell Culture
All cells with exception of human umbilical vein endothelial cells (HUVECs) were cultured in RPMI 1640 medium (Sigma-Aldrich, St. Louis, MO) supplemented with 100 µg/ml penicillin, 100 µg/ml streptomycin, 2 mM L-glutamine, and 10% heat-inactivated fetal calf serum (FCS) (PAA, Linz, Austria). All cells were grown in a humidified atmosphere at 37°C and 5% CO2 and passaged twice a week using trypsin-EDTA solution. Both primary and immortalized HUVECs were cultured in M199 medium supplemented with growth factors, heparin, and 20% FCS. The human kidney epithelial tumor cell line TCL-598 has been characterized previously (Koshelnick et al., 1997) and was a gift from the Novartis Research Institute (Vienna, Austria). The human melanoma cell line IGR37 was from P. Petzelbauer (Department of General Dermatology, Medical University of Vienna, Vienna, Austria). The OVMZ-6 cells (Lutz et al., 2001) were a kind gift from V. Magdolen (Technical University of Munich, Munich, Germany). Immortalized M6P/IGF2R-negative mouse fibroblasts were a kind gift of E. Wagner (IMP, Vienna, Austria).
HUVEC Immortalization
The second generation lentiviral vector plasmid pWPT-green fluorescent protein (GFP) was kindly provided by D. Trono (Ecole Polytechnique Fédérale de Lausanne School of Life Sciences, Lausanne, Switzerland). Human telomerase reverse transcriptase (hTERT)-cDNA was inserted into pWPT-GFP between BamHI and SalI. Lentiviral particles were generated as described previously (Naldini et al., 1996). Viral supernatants were harvested 2, 3, and 4 d after transfection, filtered through a 0.45-µm filter, and used fresh. The infection of primary HUVECs with the viral particle containing supernatant was performed four times on four consecutive days in the presence of 8 µg/ml Polybrene (Sigma-Aldrich). The resulting immortalized HUVECs were termed HUVECtert. To control the lineage identity of HUVECtert, we tested cells for their ability to form vessel-like structures in a matrigel assay and for the induction of E-selectin upon tumor necrosis factor (TNF) treatment. Both, the induction of E-selectin by TNF and the formation of tubes in matrigel were normal compared with low-passage primary HUVECs. Furthermore, we analyzed the expression levels of CD31, CD105, CD109, and von Willebrand factor in HUVECtert, which were also comparable with primary HUVECs.
Immunoprecipitation and Immunoblotting Analysis
Cells (5 x 107) were lysed in lysis buffer (20 mM Tris-HCl, and 150 mM NaCl, pH 7.5) containing 1% NP-40 and a mixture of protease inhibitors (5 µM aprotinin, 5 µM leupeptin, 5 µM pepstatin, and 1 mM phenylmethylsulfonyl fluoride [PMSF]; all from Sigma-Aldrich). The cell lysates were subjected to immunoprecipitation using specific mAbs coated on a 96-well Falcon plastic plate via a goat anti-mouse immunoglobulin G (IgG) antibody (Sigma-Aldrich). After 3 h at 4°C, the wells were washed, and the immunoprecipitates were analyzed by SDS-polyacrylamide gel electrophoresis (PAGE) followed by transfer to Immobilon polyvinylidene difluoride membranes (Millipore, Billerica, MA). The membranes were blocked using 4% nonfat milk and immunostained with a specific mAb. For visualization of proteins, the ECL system with the Lumi-Imager (Roche Diagnostics, Mannheim, Germany) or the Odyssey infrared imaging system (LI-COR Biosciences, Lincoln, NE) was used.
Flow Cytometry
Cells were detached using 5 mM EDTA/phosphate-buffered saline (PBS). For surface staining, the cells were washed with PBS containing 1% BSA and then incubated for 30 min with specific mAbs on ice. For nonlabeled antibodies, the cells were washed again, and a second step staining was done with fluorescein isothiocyanate-conjugated F(ab')2 anti-mouse IgG + IgM antibodies (An der Grub, Kaumberg, Austria). Before analysis, the cells were washed with PBS/1% BSA. Dead cells were excluded by staining with 7-amino-actinomycin D. For intracellular staining, the cells were washed with PBS and subsequently fixed for 15 min with 4% paraformaldehyde. Then, the fixed cells were permeabilized by incubation for 15 min in PBS/5% FCS and 0.1% saponin. The staining was done on ice in the permeabilization buffer. Finally, the cells were washed twice in the permeabilization buffer. Flow cytometry was performed on an LSR II flow cytometer (BD Biosciences, Erembodegem, Belgium). Data acquisition was executed with the FACSDiva software (BD Biosciences). Data analysis was accomplished with the FlowJo software (Tree Star, Ashland, OR).
Real-Time Polymerase Chain Reaction (PCR)
RNA was extracted from cells with Tri Reagent (Sigma-Aldrich). Total RNA was then reverse transcribed into cDNA using the High Capacity RNA-to-cDNA Kit (Applied Biosystems, Foster City, CA). Finally, gene expression was quantified by real-time PCR using a LightCycler instrument (Roche Diagnostics). The following primers were used: uPA, forward 5'-TGAGGTGGAAAACCTCATCC-3' and reverse, 5'-GGCAGGCAGATGGTCTGTAT-3'; uPAR, forward 5'-ACGACACCT TCCACTTCCTG-3' and reverse, 5'-TCTCTTCAGAGGAGCATCCA-3'; integrin β1, forward 5'-TCTGCGGACAGTGTGTTTGT-3' and reverse, 5'-CGTTGCTGGCTTCACAAGTA-3'; and integrin β3, forward 5'-AGCTAGTCTGGGATCCACCTC-3' and reverse 5'-GGGGTTAGTCCTCGATGAAG-3'. Primers for integrins 4 and V and β2-macroglobulin were described previously (Arap and Huang, 1999; Gruber et al., 2003).
RNA Interference
The stable knockdown cell lines for M6P/IGF2R were generated by the delivery of a short hairpin RNA (shRNA) expression cassette. We cloned three short hairpin sequences specific for M6P/IGF2R via EcoRI/AgeI to the lentiviral vector pLKOpuro1 (provided by S. Steward, Washington University School of Medicine, St. Louis, MO): 1) sh4525 with the sequence 5'-GAGCAACGAGCATGATGACttcaagagaGTCATCATGCTCGTTGCTC-3'; 2) sh5950 with the sequence 5'-GTTGTCTGCCCTCCAAAGAttcaagagaTCTTTGGAGGGCAGACAAC-3'; and 3) sh6588 with the sequence 5'-GCCCAACGATCAGCACTTCttcaagagaGAAGTGCTGATCGTTGGGC-3'. As a control construct, we used the MISSION nontarget shRNA control vector (pLKOpuro1) from Sigma-Aldrich. Lentiviral particles were generated as described previously (Naldini et al., 1996). Briefly, human embryonic kidney (HEK)-293 cells were cotransfected by the calcium phosphate precipitation method with vector DNA (pLKOpuro1), the pseudotyping plasmid (pCMV_VSV.G), and the packaging construct (pHR'8–2deltaR) in a ratio of 2:1:1.5. Forty-eight hours after transfection, viral supernatants were harvested, filtered, and used fresh for the transduction of target cell lines. The transduction was done overnight with the addition of 5 µg/ml Polybrene. Transduced cell lines were cultured permanently with puromycin (for TCL-598, 3 µg/ml; for HUVECtert, 2 µg/ml).
To silence the expression of uPAR and V integrin, we transiently transfected the TCL-598 cells using the Amaxa Nucleofector technology (Amaxa, Cologne, Germany). The following small interfering RNAs (siRNAs) were used: Silencer-validated siRNA targeting uPAR and the Silencer Negative Control siRNA were from Ambion (Austin, TX); Integrin V siRNA was from Santa Cruz Biotechnology (Santa Cruz, CA). TCL-598 cell transfection with 1 µg of siRNA was optimized by testing various transfection programs on the Amaxa Nucleofector machine (Amaxa). The optimal transfection efficiency for TCL-598 cells was achieved with program B-24. We prepared the buffer for transfection as described previously (van den Hoff et al., 1992). Assays were generally done 48 h after transfection.
Plasmin and uPA Activity Assay
Plasmin and uPA activities were measured as described previously (Leksa et al., 2002). Briefly, the TCL-598 (5 x 104 cells/well) or HUVECtert (1 x 105 cells/well) cells were seeded in 96-well plates 24 h before the assay. For the assay, the cells were washed twice with serum-free RPMI 1640 medium, and then they were incubated at 37°C in serum-free medium together with human Glu-Plg (50 nM) and either the chromogenic plasmin (S-2251) or uPA (S-2444) substrates. The absorbance change at 405 nm was monitored at different time points by using an enzyme-linked immunosorbent assay reader (SpectraMax M5; Molecular Devices, Sunnyvale, CA). To block the activity of unbound plasmin, the assays were performed in the presence of 2-antiplasmin (2.5 µg/ml). Optionally, various inhibitors were added to the reaction. In one set of Plg activation experiments the cells were preincubated with blocking antibodies (10 µg/ml) against IGF2 or TGFβ for 24 h before the assay. Also, during the assay time (4 h), the antibodies were present in the medium. The TGFβ blocking Abs were against all three isoforms of TGFβ.
Cell Invasion Assay
Cell invasion was measured with the QCM Invasion assay kit according to the manufacturer's instructions (Millipore Bioscience Research Reagents). Briefly, the invasion assay is based on the Boyden chamber principle with filter inserts containing 8-µm pore size polycarbonate membranes coated with basement membrane matrigel matrix. Optionally, the matrigel was preincubated with inhibitors diluted in serum-free medium for 1 h at 37°C. EGF was added into the lower chambers (10 ng/ml) in RPMI 1640 medium (10% FCS). Then, the cells were seeded into the upper part of the filter (1 x 105 cells/filter) and incubated 18 h at 37°C. The number of the cells invaded onto the lower side of the filters was evaluated after staining with crystal violet either by cell counting or by lysing the crystal violet stained cells followed by measuring the relative cell numbers on an enzyme-linked immunosorbent assay (ELISA) reader (OD595, SpectraMax M5; Molecular Devices).
Cell Adhesion and Migration Assays
For cell adhesion and migration assays, the cells were harvested, washed, and resuspended in serum-free medium. For the adhesion assays, various matrix proteins were coated on a 96-well plate (Nalge Nunc International, Rochester, NY) in RPMI 1640 medium for 2 h at 37°C. Wells were blocked by using 1% BSA, washed, and then incubated with the cells (1 x 105 cells/well). After 10–20-min (TCL-598) or 60-min (OVMZ-6) incubation at 37°C, the wells were washed by immersion in a plastic tray containing PBS. Adhered cells were fixed with methanol and stained with crystal violet. After intense washings, cells were solubilized in 0.5% Triton X-100, and the number of cells was determined by measuring the absorbance at 595 nm using an ELISA reader.
Cell migration was measured in a modified Boyden chamber chemotaxis assay as described previously (Leksa et al., 2002). Briefly, the cells (5 x 104) were seeded in the upper chambers of tissue culture polycarbonate filter inserts (10 mm in diameter, 8-µm pore size; Corning Life Sciences, Lowell, MA) coated with vitronectin (10 µg/ml) and blocked with BSA. Chemoattractants (10 ng/ml EGF, 10 nM uPA, and 10 µg/ml IGF2) were added to the lower chambers of the filter inserts. After 4–15 h of incubation at 37°C, the filters were removed, the upper surface of the membrane was scraped free of cells, and the number of cells that had migrated to the lower surface was measured by crystal violet as described above.
Internalization and Biotin Chasing Assay
For the internalization assay, cells were harvested using 5 mM EDTA and washed with culture medium. Generally, the cells were put in suspension back to the incubator for at least 1 h after the EDTA treatment. Then, the cells were washed and stained on ice for 30 min with the uPAR mAb H2 conjugated with Alexa Fluor 488. After staining, the cells were washed with PBS and resuspended in 100 µl of DMEM containing 1% BSA and 10 mM HEPES. Stained cells were incubated either on ice or for various times at 37°C to allow internalization. Afterward, the cells were stripped or not for 3 min in 0.5 M NaCl and 0.2 M acetic acid. The stripped cells were washed twice in DMEM with 1% BSA and 10 mM HEPES. Then, the remaining (stripping-resistant) fluorescence was analyzed by flow cytometry. The internalization rate was calculated as a percentage of remaining fluorescence intensity after the stripping.
The biotin-chasing assay was done with either EDTA-detached or adherent cells that were washed with ice-cold PBS and cell surface biotinylated for 30 min on ice with 0.5 µg/ml biotin. Incubation of the cells for 10 min with 100 µM glycine in PBS stopped biotinylation. Then, the cells were washed two times and incubated in RPMI 1640 medium (10% FCS). Optionally, uPA, Plg, or the uPA inhibitor amiloride, a mixture of the serine protease inhibitors aprotinin and PMSF, or PAI-1 was added. After different times at 37°C, the incubation was stopped and the cells were lysed in radioimmunoprecipitation assay buffer. Then, the cell surface biotinylated proteins were precipitated with streptavidin beads for 2 h on 4°C. After washing the beads, the eluted precipitates were analyzed by SDS-PAGE and Western blotting. The bands on the immunoblot were quantified by analyzing the integrated intensity on the Odyssey infrared imaging system (LI-COR Biosciences). Values corresponding to full-length uPAR were normalized to β1 integrin bands. The normalized value at time 0 was set as 100%, and the percentage of degradation over time was calculated.
Statistical Analysis
The experiments were performed at least two times in at least triplicates, and the data were expressed as mean values with SD. Statistical significance was evaluated using a two-tailed, paired Student's t test; a value of *p < 0.05 or **p < 0.005 (as indicated) was considered to be significant.
|
RESULTS |
|---|
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Vβ3, and Cell Surface Binding of uPA and Plg). To perform loss of function studies, we used RNA interference to down-regulate M6P/IGF2R. TCL-598 cells were transduced with lentiviral constructs containing shRNA expression cassettes against M6P/IGF2R, leading to a stable silencing of the receptor. The most effective construct targeting M6P/IGF2R mRNA at the position 6588 resulted in a silencing efficiency of 
90% at the protein level and was used throughout the study (Supplemental Figure S1A and S1D). Another target position (sh4525) was almost equally efficient (80% silencing efficiency), and importantly, we obtained similar results also with this target site (Supplemental Figure S1B, S1C, and S1E). Thus, we can exclude sequence-dependent nonspecific shRNA effects on the cells throughout our experiments. As a control, we used a scrambled nonspecific shRNA and in some experiments additionally the shRNA targeting position 5950 (sh5950), which did not repress M6P/IGF2R expression (Supplemental Figure S1).
Flow cytometry analysis revealed up-regulation of both surface and total pro-uPA/uPA in the M6P/IGF2R-silenced cells (24 and 35%; n = 3). We observed no change in the uPAR surface staining although the total protein amount was increased in the knockdown cells (38%; n = 3). Surface and total protein levels of Vβ3 integrin, which serves as alternative receptor for uPA (Tarui et al., 2006), were also higher in knockdown cells (40 and 35%, respectively; n = 3) (Figure 1A). Other receptors such as β1 integrin or MHC class I remained unaffected.
|
V integrin in immortalized human umbilical vein endothelial cells (HUVECtert) silenced for M6P/IGF2R expression (48 and 39%, respectively; n = 2) (Figure 3A). In these cells, we observed a stronger up-regulation of beta1 integrin expression (45%) than β3 (25%).
To test whether the up-regulation of uPA/uPAR and Vβ3 expression in TCL-598 cells was due to reduced protein turnover or enhanced mRNA levels, we quantified the respective mRNAs by real-time PCR. The uPA and Vβ3 message was significantly higher in M6P/IGF2R knockdown cells, whereas 4 and β1 mRNA were not affected (Figure 1B; n = 3). Interestingly, also the uPAR mRNA was unchanged, although we found by flow cytometry the total protein amount in the silenced cells enhanced.
Because M6P/IGF2R, uPA as well as Vβ3 have been described as Plg receptors (Ellis et al., 1999; Godar et al., 1999; Tarui et al., 2002), we tested next how the M6P/IGF2R knockdown changed the Plg binding capacity of the cells. We incubated the cells with Cy5-labeled Plg and analyzed the binding by flow cytometry. We found the Plg binding capacity to be higher by 35% on M6P/IGF2R-silenced cells (Figure 1C; n = 3; p = 0.03).
Enhanced Plasmin Activity and Invasion of M6P/IGF2R-silenced Cells Is Mediated by uPAR
Next, we measured the proteolytic activity of plasmin and uPA on the M6P/IGF2R knockdown TCL-598 cells. All assays were done in the presence of 2-antiplasmin (2.5 µg/ml), an inhibitor of unbound plasmin, to measure only the cell surface-associated proteolytic activity. The activity of both uPA and plasmin was significantly higher in the M6P/IGF2R knockdown cells (67 and 50% respectively; n = 3; Figure 2, A and B, and Supplemental Figure S1). This enhanced proteolytic activity was sensitive to the lysine analogue TA (an inhibitor of the lysine-dependent binding of Plg onto the cell surface), the uPA inhibitor amiloride, and the serine protease inhibitor aprotinin. In contrast, the inhibitors of cysteine and aspartic acid proteases (IAA and pepstatin A) and matrix metalloproteinases (galardin) did not change the enhanced proteolytic activity of M6P/IGF2R knockdown cells (Figure 2, A and B). This excludes the possibility that either enhanced secretion or reduced internalization of cathepsin B, C, and L, which were shown to activate pro-uPA, was responsible for the observed phenotype. The enhanced cell surface plasmin activity on M6P/IGF2R knockdown cells was also not affected by blocking IGF2 and TGFβ (Figure 2C; n = 2), excluding an autocrine IGF2 or TGFβ stimulation influencing the Plg activation system.
|
|
The enhanced proteolysis and cell invasion observed in Figures 2 and 3 could be explained by the increased uPA/uPAR levels (Figures 1, A and B, and 3A) and/or the higher Plg binding capacity (Figure 1C) of the M6P/IGF2R knockdown cells. Furthermore, Vβ3 integrin, also up-regulated in these cells (Figure 1, A and B), was shown to bind both uPA and plasmin (Tarui et al., 2002, 2006) and could thus be as well in charge. To test this, we generated double and triple knockdown TCL-598 cells (Figure 4A). First, we again tested the Plg activation capacity of the cells. The latter knockdown phenotype was completely rescued by cosilencing uPAR, whereas the V integrin/M6P/IGF2R double-silenced cells still held higher plasmin activity than the control cells (Figure 4B; n = 3). Also in these experiments, plasmin activity was entirely sensitive to the uPA inhibitor amiloride. Next, we analyzed the contribution of uPAR and V integrins to the enhanced cell invasion in M6P/IGF2R knockdown cells. Both, uPAR and V cosilencing significantly rescued the enhanced cell invasion observed (Figure 4, C and D), indicating that also the enhanced V expression on M6P/IGF2R silenced cells contributed to the increase in cell invasion. Of note, we found a significant reduction of both uPA and Plg binding to the cell surface of uPAR-silenced cells but not to V-silenced cells (Supplemental Figure S2). These findings strongly suggest that M6P/IGF2R regulates pericellular Plg activation by acting directly on uPAR.
|
; Madsen and Sidenius, 2008). In all cell lines in which we targeted M6P/IGF2R, we observed a marked increase in cell spreading under normal culture conditions. This could be attributed to the up-regulation of V integrins or a change in vitronectin binding to uPAR. To address this issue, we performed a cell adhesion assay on different matrix proteins. In addition to the TCL-598 cells that are very sticky and highly adhesive, we have chosen the OVMZ-6 ovarian carcinoma cell line, which possesses very low basal adhesiveness to most matrix proteins compared with TCL-598 cells. We silenced the expression of M6P/IGF2R in OVMZ-6 cells by shRNA expression as we did in TCL-598 cells (Supplemental Figure S1D). M6P/IGF2R silenced OVMZ-6 as well as TCL-598 cells displayed significantly higher adhesiveness to vitronectin, fibronectin, and collagen type IV compared with control cells (Figure 5, A and C). Of these matrix proteins, only vitronectin is a ligand for uPAR; thus, these data indicated that rather the enhanced expression and/or activity of the V family integrin heterodimers was responsible for the increased cell adhesion of M6P/IGF2R knockdown cells. To confirm this assumption we again used double-silenced cells deficient for both M6P/IGF2R and uPAR or V integrins. Silencing of V resulted in loss of adhesion to vitronectin in control cells and in a significant reduction of the enhanced adhesion of M6P/IGF2R-silenced cells. We did not observe a complete rescue of the M6P/IGF2R knockdown phenotype, probably due to incomplete silencing of V integrin (Figure 5B). Interestingly, we did not see any effect of uPAR silencing on cell adhesion to vitronectin.
|
Vβ3 integrin and induce cell motility by activating Rac1 and Cdc42 (Wei et al., 2008). To test whether M6P/IGF2R silencing also affected tumor cell motility, we subjected silenced TCL-598 and OVMZ-6 cells to a Boyden chamber chemotaxis assay and compared them with control cells. The Boyden chamber filters were precoated with vitronectin. TCL-598 cells showed very high basal migratory capacity (overnight transmigration 10–20% of total cells without any chemoattractant). For OVMZ-6 cells (no basal migration overnight), we used human pro-uPA, IGF2, and EGF as chemoattractants. Both OVMZ-6 and TCL-598 were found to significantly transmigrate with an enhanced rate upon M6P/IGF2R knockdown (Figure 5D).
uPAR Cleavage but Not uPAR Internalization and Turnover Is Dependent on M6P/IGF2R Expression: M6P/IGF2R Accelerates uPAR Cleavage
uPAR is present on the surface of cells as a full-length 3-domain molecule (D1D2D3), capable of binding pro-uPA/uPA, or a truncated variant (D2D3), lacking the pro-uPA/uPA binding domain D1. Coimmunoprecipitation analysis revealed that M6P/IGF2R interacted preferentially with the intact full-length three-domain form of uPAR in TCL-598 cells (Figure 6A). In addition, we found M6P/IGF2R in a complex also with V integrin (Figure 6B).
|
|
), it could have been possible that the abundance of full-length uPAR on the silenced cells was due to diminished internalization of the full-length uPAR enriching relative expression of the truncated D2D3 form. However, we did not find any significant defect in uPAR internalization rates upon M6P/IGF2R knockdown (Figure 8A; n = 4).
|
; Beaufort et al., 2004). Because M6P/IGF2R binds both uPAR and Plg (Godar et al., 1999; Leksa et al., 2002), we asked whether M6P/IGF2R could influence the uPAR cleavage rate. Therefore, we chased the stability of cell surface uPAR on surface biotinylated TCL-598 cells for various times at 37°C. Afterward, the cells were lysed and biotinylated proteins were precipitated with streptavidin. The precipitates were analyzed by SDS-PAGE and immunoblotting for occurrence of full-length uPAR (Figure 8B). We found that the stability of full-length uPAR (D1D2D3) was significantly enhanced in M6P/IGF2R-silenced cells at the onset of the experiment (within the first hour) (Figure 8C). This difference was due to reduced cleavage of uPAR in M6P/IGF2R knockdown cells, as shown by the sensitivity of the D1D2D3 stability to the uPA inhibitor amiloride (Figure 8C), aprotinin/PMSF and PAI1 (Supplemental Figure S2). At later times of the biotin chase experiment (4 h), we did not observe any difference in uPAR stability between control and M6P/IGF2R knockdown cells (Figure 8C). The bands corresponding to full-length uPAR were normalized to β1 integrin, which was used as a loading control because we did not observe any M6P/IGF2R-dependent changes in the β1 integrin turnover (Supplemental Figure S3A and S3C). In the same way, we analyzed also the turnover of β3 integrin by chasing cell surface biotinylated integrins. The surface-biotinylated cell lysates were precipitated with streptavidin beads and the integrins were analyzed by Western blotting (Supplemental Figure S3B). By quantifying the biotinylated integrins, we could calculate the rate of degradation during the chasing experiment (Supplemental Figure S3D). The protein turnover rate of β3 integrin was not changed upon M6P/IGF2R knockdown in TCL-598 cells.
To confirm the dependence of uPAR cleavage on M6P/IGF2R, we used mouse embryonic fibroblasts from M6P/IGF2R knockout mice transduced with human uPAR either alone or together with human M6P/IGF2R. The latter cells displayed significantly reduced Plg activatory capacity compared with the former cells (Leksa et al., 2002). In contrast to TCL-598 cells, these cells do not produce human uPA. When biotinylated, both uPAR+ and uPAR+/M6P/IGF2R+ cells expressed predominantly the full-length variant of cell surface uPAR. When we performed the chasing experiments in the presence of active uPA, we found that surface biotinylated uPAR was rapidly cleaved, especially when M6P/IGF2R was coexpressed (Figure 8D; n = 3). Similar to TCL-598 cells silenced for M6P/IGF2R expression, the mouse fibroblasts expressing human uPAR alone displayed significantly higher stability of the full-length D1D2D3 uPAR compared with the cells coexpressing human M6P/IGF2R (Figure 8E; n = 3).
|
DISCUSSION |
|---|
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Vβ3 integrin are critically involved in tumor-associated angiogenesis and tumor spreading (Mazar et al., 1999; Felding-Habermann et al., 2001; Felding-Habermann et al., 2002; Pilch et al., 2002; Rolli et al., 2003; Dano et al., 2005; Dass et al., 2008). Our results demonstrate that M6P/IGF2R functions as a negative regulator of the uPAR/Plg system and V integrin expression in human cancer and endothelial cells. First, the M6P/IGF2R interacts with full-length uPAR and facilitates its cleavage, thereby reducing the uPA/Plg binding capacity of cells. Second, the M6P/IGF2R knockdown induces up-regulation of the V integrins and cell adhesion to its ligands.
Consistent with the up-regulation of uPA and Plg binding to the cell surface, M6P/IGF2R knockdown cells exhibited enhanced pericellular plasmin activity and higher invasive capacity (Figures 1
–3). As shown by the genetic rescue experiments using M6P/IGF2R-uPAR-V double/triple knockdown cells (Figure 4), both the enhanced uPAR-mediated Plg activation and the enhanced V integrin expression contributed to an increase in cell invasion of M6P/IGF2R knockdown cells. Interestingly, silencing Vβ3 did not affect Plg activation, even though Vβ3 expression has been shown to enhance Plg activation on cells by binding both uPA and plasmin (Tarui et al., 2002, 2006). Conversely, cosilencing either uPAR or V integrin in M6P/IGF2R-silenced cells revealed that the enhanced adhesion to vitronectin was mediated by V integrin and not uPAR. A direct and strong function of uPAR in tumor cell adhesion to vitronectin is therefore not supported by our results, which is also in agreement with the findings of a recent report (Smith et al., 2008).
Various cathepsins promote tumor invasiveness directly via degradation of extracellular matrix components or via activation of other proteinases, such as pro-uPA (Kobayashi et al., 1991; Ravanko et al., 2004). In addition, autocrine stimulation by IGF2 or TGFβ might influence the Plg activation system (Leivonen and Kahari, 2007; Samani et al., 2007). Still, M6P/IGF2R-silenced cells held their phenotype compared with control cells in the presence of cathepsin inhibitors and IGF2/TGFβ-specific blocking antibodies (Figure 2). We therefore conclude that M6P/IGF2R regulates Plg activation and cell invasion via a direct effect on uPAR. The tumor cells used in our study produced high amounts of pro-uPA and expressed uPAR. In tumor cells producing low or no pro-uPA/uPAR, different suppressor functions of M6P/IGF2R could be decisive; for example, the lack of M6P/IGF2R could contribute to tumor cell invasiveness through impaired intracellular trafficking of cathepsins (Lorenzo et al., 2000) or through degradation of IGF2 (MacDonald and Byrd, 2003; Guvakova, 2007).
In the coimmunoprecipitation experiments M6P/IGF2R had a strong preference to bind only full-length uPAR (Figure 6B). Similarly, just the intact full-length uPAR binds uPA (Behrendt et al., 1991), vitronectin (Hoyer-Hansen et al., 1997), and integrins (Montuori et al., 2002). A coimmunoprecipitation of M6P/IGF2R only with full-length uPAR is in conflict with the findings of Nykjaer et al. (1998) who found also D2D3 interacting with M6P/IGF2R. This discrepancy could be due to the fact that in contrast to Nykjaer and colleagues, we did not use a chemical cross-linker before the immunoprecipitation. We cannot exclude a possible interaction of D2D3 with M6P/IGF2R; however, we propose that there is a preference for the full-length form. In vitro binding assays of truncated uPAR variants revealed that even domain 1 alone could bind to M6P/IGF2R. This interaction was strengthened by the presence of domain 2 and 3, suggesting that there might be multiple binding sites within the three different uPAR domains for M6P/IGF2R (data not shown).
In addition to the enhanced proteolytic capacity of M6P/IGF2R knockdown cells, the concomitant up-regulation of both uPA/uPAR and Vβ3 in these cells might feed a positive feedback loop leading to integrin activation. The binding of uPAR to the matrix protein vitronectin was proposed to feed integrin activation (Madsen et al., 2007). Indeed, it has been recently shown that uPAR on podocytes activates Vβ3 in a vitronectin and lipid-dependent manner (Wei et al., 2008). Furthermore, the engagement of V integrin by its ligand vitronectin led to induction of p38 and enhanced uPA expression in the invasive breast cancer cell line MDA-MB-231 (Chen et al., 2001). The observed up-regulation of both V integrin and uPA/uPAR in the M6P/IGF2R knockdown cells suggest a molecular and functional overlap of uPA/uPAR, M6P/IGF2R, and Vβ3. In this respect, it was also very interesting to find M6P/IGF2R coimmunoprecipitated with Vβ3 integrin (Figure 6). We did not find any binding of purified M6P/IGF2R to purified Vβ3 in vitro (data not shown), indicating that the interaction in cells is dependent on lipids and/or other third party molecules. Given that M6P/IGF2R is known for targeting some of its ligands to lysosomes, we analyzed the turnover rate of both β1 and β3 integrins; this was not changed upon M6P/IGF2R knockdown (Supplemental Figure S3). However, the level of V mRNA was enhanced in M6P/IGF2R silenced cells as determined by real-time PCR (Figure 1).
Two processes are described for internalization of uPAR: the first is dependent on a member of the LDL receptor family, such as the LDL-related protein and leads rather to reactivation instead of termination of uPAR functions during cell migration (Nykjaer et al., 1997; Prager et al., 2004). The second mechanism was proposed to be particularly dependent on M6P/IGF2R, targeting uPAR to lysosomes (Nykjaer et al., 1998). This could be done either via direct internalization from the cell surface or sorting from endosomal compartments. Based on our data, the steady-state cell surface internalization rate of uPAR is not changed in M6P/IGF2R-silenced cells (Figure 8A). This could be explained by a sufficient redundancy with other internalization pathways. However, if M6P/IGF2R mediated the clearance of uPAR from the cell surface by internalization and transport to lysosomes, we would expect an enriched cell surface expression in M6P/IGF2R-silenced cells. We never observed altered surface expression of uPAR (D1D2D3 + D2D3) in M6P/IGF2R knockdown compared with control cells; instead, the ratio of full-length (D1D2D3) to truncated uPAR (D2D3) was changed (Figure 7). The function of M6P/IGF2R in lysosomal targeting of full-length uPAR cannot explain reduction of D2D3 in M6P/IGF2R knockdown cells.
As stated above, the TCL-598 tumor cell line used in this study secretes pro-uPA, and active uPA is known to cleave full-length uPAR on the surface of cells (Hoyer-Hansen et al., 1992). In addition, plasmin can also cleave uPAR (Beaufort et al., 2004). The cleavage of uPAR within the linker sequence of D1 and D2 was clearly shown to interfere with most of the uPAR functions (Montuori et al., 2002, 2005); yet, under some circumstances the cleavage could also induce active processes such as the induction of chemotaxis via a G protein-coupled receptor (Resnati et al., 2002) or the induction of myofibroblast differentiation (Bernstein et al., 2007). Because uPA is a ligand for uPAR, and Plg can bind both M6P/IGF2R and uPA, the local accumulation of uPA and plasmin on the uPAR–M6P/IGF2R receptor complex might amplify the cleavage leading to loss of the uPA-binding site. In fact, a chasing assay revealed that M6P/IGF2R-silenced cells display reduced cleavage of D1D2D3 to D2D3 at early time points (within 1 h) of the biotin chase (Figure 8). The cleavage was almost completely blocked by the uPA inhibitor amiloride, a mixture of the serine protease inhibitors aprotinin and PMSF, and partially blocked by addition of PAI-1 (Supplemental Figure S4), indicating that the cleavage is mediated or initiated by active uPA. uPAR seems to be more cleaved when dimerized within lipid rafts (Cunningham et al., 2003) and complexed with integrins (Mazzieri et al., 2006). To what extend these observations explain the role of M6P/IGF2R in uPAR cleavage needs future investigations. It might also be that the conformation of uPAR is changed by the interaction with M6P/IGF2R, thereby enhancing the cleavage rate. The fact that at later time points (starting at 2 h) of the biotin chase the initial difference in the cleavage kinetic is lost is very interesting. Cunningham et al. (2003) have shown that the half-life of uPAR (D1D2D3) upon addition of uPA to cells is only between 15 min (inside lipid rafts) and 1 h (outside lipid rafts). Exactly within this time frame we see a significantly slower decline in the level of biotinylated D1D2D3 in M6P/IGF2R knockdown cells (Figure 8C). Mouse fibroblasts overexpressing M6P/IGF2R showed the opposite phenotype (Figure 8E). This clearly indicates that the cell surface turnover of D1D2D3 by its cleavage is influenced by M6P/IGF2R expression.
After internalization, uPAR may be recycled back to the cell surface or degraded in lysosomes or by the proteasome. The later time points in Figure 8C (4–48 h) visualize that the turnover rate of biotinylated uPAR, which in addition to the cleavage of D1D2D3 to D2D3 also involves lysosomal and/or proteasomal degradation, is unchanged in M6P/IGF2R knockdown cells. These results are in divergence with a nonredundant function of M6P/IGF2R in mediating the lysosomal degradation of uPAR (Nykjaer et al., 1998). In line with this, we also did not find a reduced accumulation of uPAR in lysosomes of M6P/IGF2R knockdown cells (data not shown). Resistance to uPAR cleavage in M6P/IGF2R knockdown cells might also have important implications for the nature of uPA signaling in these cells. Using a cleavage-resistant mutant of uPAR Mazzieri et al. (2006) showed that reduced cleavage of uPAR favored epidermal growth factor receptor phosphorylation upon addition of uPA to cells (Mazzieri et al., 2006).
Together, tumor cells loosing M6P/IGF2R expression become deficient in negative feedback regulation of the Plg activation system via uPAR cleavage resulting in enhanced invasive potential. We propose that the regulation of uPAR cleavage and V integrin expression by M6P/IGF2R could explain its potential role as a metastasis suppressor. Observations in clinical and experimental studies support this view. For example, the M6P/IGF2R expression was found decreased in invasive carcinomas relative to adjacent normal tissue and high-grade ductal carcinomas in situ in a breast cancer study (Berthe et al., 2003). Furthermore, the overexpression of M6P/IGF2R in breast cancer cells reduced their invasive potential through Matrigel (Lee et al., 2003). Recently, it has been shown that M6P/IGF2R is down-regulated by the major tumor promoting factor SATB1 (Han et al., 2008). It was also shown that the regulation of uPAR cleavage might influence tumor progression. For example, highly invasive follicular thyroid carcinoma cells expressed the intact form uPAR, whereas less aggressive papillary carcinoma cells as well as benign thyroid tumor cells and nonneoplastic cells expressed large amounts of cleaved uPAR (Ragno et al., 1998). We conclude that under in vivo conditions with high uPA/uPAR levels present, the M6P/IGF2R status of tumor cells might predict the invasive potential of these cells.
|
ACKNOWLEDGMENTS |
|---|
rejí for mAbs MEM-238 and MEM-240 against M6P/IGF2R and MEM-101A against β1 integrin, U. Weidle for mAbs C8 and H2 against uPAR, S. Stewart for the lentiviral vector pLKOpuro1, and D. Trono for the second generation lentiviral vector plasmids. This work was supported by the Austrian Science Fund (grant P19014-B13 and Program Project Grant SFBF005), grants from the Science and Technology Assistance Agency (APVT-51–026204), the Slovak Grant Agency VEGA (2/5119/25), the Bilateral Cooperation Slovakia-Austria (SK-11-AUT-9), the Competence Centre for Biomolecular Therapeutics (BMT) and the GEN-AU program of the Austrian Federal Ministry of Science and Research. |
Footnotes |
|---|
Address correspondence to: Vladimir Leksa (vladimir.leksa{at}meduniwien.ac.at)
Abbreviations used: IGF, insulin-like growth factor; M6P/IGF2R, mannose 6-phosphate/insulin-like growth factor 2 receptor; Plg, plasminogen; PAI, plasminogen activator inhibitor; shRNA, short hairpin RNA; TGF, transforming growth factor; uPA, urokinase-type plasminogen activator; uPAR, urokinase-type plasminogen activator receptor.
|
REFERENCES |
|---|
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Beaufort, N., Leduc, D., Rousselle, J. C., Namane, A., Chignard, M., and Pidard, D. (2004). Plasmin cleaves the juxtamembrane domain and releases truncated species of the urokinase receptor (CD87) from human bronchial epithelial cells. FEBS Lett 574, 89–94.[CrossRef][Medline]
Behrendt, N., Ploug, M., Patthy, L., Houen, G., Blasi, F., and Dano, K. (1991). The ligand-binding domain of the cell surface receptor for urokinase-type plasminogen activator. J. Biol. Chem 266, 7842–7847.
Bernstein, A. M., Twining, S. S., Warejcka, D. J., Tall, E., and Masur, S. K. (2007). Urokinase receptor cleavage: a crucial step in fibroblast-to-myofibroblast differentiation. Mol. Biol. Cell 18, 2716–2727.
Berthe, M. L., Esslimani Sahla, M., Roger, P., Gleizes, M., Lemamy, G. J., Brouillet, J. P., and Rochefort, H. (2003). Mannose-6-phosphate/insulin-like growth factor-II receptor expression levels during the progression from normal human mammary tissue to invasive breast carcinomas. Eur. J. Cancer 39, 635–642.[CrossRef][Medline]
Chen, J., Baskerville, C., Han, Q., Pan, Z. K., and Huang, S. (2001). (v) Integrin, p38 mitogen-activated protein kinase, and urokinase plasminogen activator are functionally linked in invasive breast cancer cells. J. Biol. Chem 276, 47901–47905.
Cunningham, O., Andolfo, A., Santovito, M. L., Iuzzolino, L., Blasi, F., and Sidenius, N. (2003). Dimerization controls the lipid raft partitioning of uPAR/CD87 and regulates its biological functions. EMBO J 22, 5994–6003.[CrossRef][Medline]
Dano, K., Behrendt, N., Hoyer-Hansen, G., Johnsen, M., Lund, L. R., Ploug, M., and Romer, J. (2005). Plasminogen activation and cancer. Thromb. Haemost 93, 676–681.[Medline]
Dass, K., Ahmad, A., Azmi, A. S., Sarkar, S. H., and Sarkar, F. H. (2008). Evolving role of uPA/uPAR system in human cancers. Cancer Treat. Rev 34, 122–136.[CrossRef][Medline]
Dennis, P. A., and Rifkin, D. B. (1991). Cellular activation of latent transforming growth factor beta requires binding to the cation-independent mannose 6-phosphate/insulin-like growth factor type II receptor. Proc. Natl. Acad. Sci. USA 88, 580–584.
Ellis, V., Whawell, S. A., Werner, F., and Deadman, J. J. (1999). Assembly of urokinase receptor-mediated plasminogen activation complexes involves direct, non-active-site interactions between urokinase and plasminogen. Biochemistry 38, 651–659.[CrossRef][Medline]
Felding-Habermann, B., Fransvea, E., O'Toole, T. E., Manzuk, L., Faha, B., and Hensler, M. (2002). Involvement of tumor cell integrin alpha v beta 3 in hematogenous metastasis of human melanoma cells. Clin. Exp. Metastasis 19, 427–436.[CrossRef][Medline]
Felding-Habermann, B. et al. (2001). Integrin activation controls metastasis in human breast cancer. Proc. Natl. Acad. Sci. USA 98, 1853–1858.
Ghosh, P., Dahms, N. M., and Kornfeld, S. (2003). Mannose 6-phosphate receptors: new twists in the tale. Nat. Rev. Mol. Cell Biol 4, 202–212.[CrossRef][Medline]
Godar, S., Horejsi, V., Weidle, U. H., Binder, B. R., Hansmann, C., and Stockinger, H. (1999). M6P/IGFII-receptor complexes urokinase receptor and plasminogen for activation of transforming growth factor-beta1. Eur. J. Immunol 29, 1004–1013.[CrossRef][Medline]
Gruber, F. et al. (2003). Direct binding of Nur77/NAK-1 to the plasminogen activator inhibitor 1 (PAI-1) promoter regulates TNF alpha-induced PAI-1 expression. Blood 101, 3042–3048.
Guvakova, M. A. (2007). Insulin-like growth factors control cell migration in health and disease. Int. J. Biochem. Cell Biol 39, 890–909.[CrossRef][Medline]
Han, H. J., Russo, J., Kohwi, Y., and Kohwi-Shigematsu, T. (2008). SATB1 reprogrammes gene expression to promote breast tumour growth and metastasis. Nature 452, 187–193.[CrossRef][Medline]
Hebert, E. (2006). Mannose-6-phosphate/insulin-like growth factor II receptor expression and tumor development. Biosci. Rep 26, 7–17.[CrossRef][Medline]
Hoyer-Hansen, G., Behrendt, N., Ploug, M., Dano, K., and Preissner, K. T. (1997). The intact urokinase receptor is required for efficient vitronectin binding: receptor cleavage prevents ligand interaction. FEBS Lett 420, 79–85.[CrossRef][Medline]
Hoyer-Hansen, G., Ronne, E., Solberg, H., Behrendt, N., Ploug, M., Lund, L. R., Ellis, V., and Dano, K. (1992). Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain. J. Biol. Chem 267, 18224–18229.
Kang, J. X., Li, Y., and Leaf, A. (1997). Mannose-6-phosphate/insulin-like growth factor-II receptor is a receptor for retinoic acid. Proc. Natl. Acad. Sci. USA 94, 13671–13676.
Kasper, D., Dittmer, F., von Figura, K., and Pohlmann, R. (1996). Neither type of mannose 6-phosphate receptor is sufficient for targeting of lysosomal enzymes along intracellular routes. J. Cell Biol 134, 615–623.
Kobayashi, H., Schmitt, M., Goretzki, L., Chucholowski, N., Calvete, J., Kramer, M., Gunzler, W. A., Janicke, F., and Graeff, H. (1991). Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (Pro-uPA). J. Biol. Chem 266, 5147–5152.
Koshelnick, Y., Ehart, M., Hufnagl, P., Heinrich, P. C., and Binder, B. R. (1997). Urokinase receptor is associated with the components of the JAK1/STAT1 signaling pathway and leads to activation of this pathway upon receptor clustering in the human kidney epithelial tumor cell line TCL-598. J. Biol. Chem 272, 28563–28567.
Kreiling, J. L., Byrd, J. C., Deisz, R. J., Mizukami, I. F., Todd, R. F., 3rd, and MacDonald, R. G. (2003). Binding of urokinase-type plasminogen activator receptor (uPAR) to the mannose 6-phosphate/insulin-like growth factor II receptor: contrasting interactions of full-length and soluble forms of uPAR. J. Biol. Chem 278, 20628–20637.
Lee, J. S., Weiss, J., Martin, J. L., and Scott, C. D. (2003). Increased expression of the mannose 6-phosphate/insulin-like growth factor-II receptor in breast cancer cells alters tumorigenic properties in vitro and in vivo. Int. J. Cancer 107, 564–570.[CrossRef][Medline]
Leivonen, S. K., and Kahari, V. M. (2007). Transforming growth factor-beta signaling in cancer invasion and metastasis. Int. J. Cancer 121, 2119–2124.[CrossRef][Medline]
Leksa, V., Godar, S., Cebecauer, M., Hilgert, I., Breuss, J., Weidle, U. H., Horejsi, V., Binder, B. R., and Stockinger, H. (2002). The N terminus of mannose 6-phosphate/insulin-like growth factor 2 receptor in regulation of fibrinolysis and cell migration. J. Biol. Chem 277, 40575–40582.
Leksa, V. et al. (2005). TGF-{beta}-induced apoptosis in endothelial cells mediated by M6P/IGFII-R and mini-plasminogen. J. Cell Sci 118, 4577–4586.
Lorenzo, K., Ton, P., Clark, J. L., Coulibaly, S., Mach, L. et al. (2000). Invasive properties of murine squamous carcinoma cells: secretion of matrix-degrading cathepsins is attributable to a deficiency in the mannose 6-phosphate/insulin-like growth factor II receptor. Cancer Res 60, 4070–4076.
Lutz, V., Reuning, U., Kruger, A., Luther, T., von Steinburg, S. P., Graeff, H., Schmitt, M., Wilhelm, O. G., and Magdolen, V. (2001). High level synthesis of recombinant soluble urokinase receptor (CD87) by ovarian cancer cells reduces intraperitoneal tumor growth and spread in nude mice. Biol. Chem 382, 789–798.[CrossRef][Medline]
MacDonald, R. G., and Byrd, J. C. (2003). The insulin-like growth factor II/mannose 6-phosphate receptor: implications for IGF action in breast cancer. Breast Dis 17, 61–72.[Medline]
Madsen, C. D., Ferraris, G. M., Andolfo, A., Cunningham, O., and Sidenius, N. (2007). uPAR-induced cell adhesion and migration: vitronectin provides the key. J. Cell Biol 177, 927–939.
Madsen, C. D., and Sidenius, N. (2008). The interaction between urokinase receptor and vitronectin in cell adhesion and signalling. Eur. J. Cell Biol 87, 617–629.[CrossRef][Medline]
Mazar, A. P., Henkin, J., and Goldfarb, R. H. (1999). The urokinase plasminogen activator system in cancer: implications for tumor angiogenesis and metastasis. Angiogenesis 3, 15–32.[CrossRef][Medline]
Mazzieri, R., D'Alessio, S., Kenmoe, R. K., Ossowski, L., and Blasi, F. (2006). An uncleavable uPAR mutant allows dissection of signaling pathways in uPA-dependent cell migration. Mol. Biol. Cell 17, 367–378.
Montuori, N., Carriero, M. V., Salzano, S., Rossi, G., and Ragno, P. (2002). The cleavage of the urokinase receptor regulates its multiple functions. J. Biol. Chem 277, 46932–46939.
Montuori, N., Visconte, V., Rossi, G., and Ragno, P. (2005). Soluble and cleaved forms of the urokinase-receptor: degradation products or active molecules? Thromb. Haemost 93, 192–198.[Medline]
Motyka, B. et al. (2000). Mannose 6-phosphate/insulin-like growth factor II receptor is a death receptor for granzyme B during cytotoxic T cell-induced apoptosis. Cell 103, 491–500.[CrossRef][Medline]
Naldini, L., Blomer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F. H., Verma, I. M., and Trono, D. (1996). In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272, 263–267.[Abstract]
Nykjaer, A., Christensen, E. I., Vorum, H., Hager, H., Petersen, C. M., Roigaard, H., Min, H. Y., Vilhardt, F., Moller, L. B., Kornfeld, S., and Gliemann, J. (1998). Mannose 6-phosphate/insulin-like growth factor-II receptor targets the urokinase receptor to lysosomes via a novel binding interaction. J. Cell Biol 141, 815–828.
Nykjaer, A., Conese, M., Christensen, E. I., Olson, D., Cremona, O., Gliemann, J., and Blasi, F. (1997). Recycling of the urokinase receptor upon internalization of the uPA:serpin complexes. EMBO J 16, 2610–2620.[CrossRef][Medline]
Pilch, J., Habermann, R., and Felding-Habermann, B. (2002). Unique ability of integrin alpha(v)beta 3 to support tumor cell arrest under dynamic flow conditions. J. Biol. Chem 277, 21930–21938.
Prager, G. W., Breuss, J. M., Steurer, S., Olcaydu, D., Mihaly, J., Brunner, P. M., Stockinger, H., and Binder, B. R. (2004). Vascular endothelial growth factor receptor-2-induced initial endothelial cell migration depends on the presence of the urokinase receptor. Circ. Res 94, 1562–1570.
Ragno, P. (2006). The urokinase receptor: a ligand or a receptor? Story of a sociable molecule. Cell Mol. Life Sci 63, 1028–1037.[CrossRef][Medline]
Ragno, P., Montuori, N., Covelli, B., Hoyer-Hansen, G., and Rossi, G. (1998). Differential expression of a truncated form of the urokinase-type plasminogen-activator receptor in normal and tumor thyroid cells. Cancer Res 58, 1315–1319.
Ravanko, K., Jarvinen, K., Helin, J., Kalkkinen, N., and Holtta, E. (2004). Cysteine cathepsins are central contributors of invasion by cultured adenosylmethionine decarboxylase-transformed rodent fibroblasts. Cancer Res 64, 8831–8838.
Resnati, M., Pallavicini, I., Wang, J. M., Oppenheim, J., Serhan, C. N., Romano, M., and Blasi, F. (2002). The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R. Proc. Natl. Acad. Sci. USA 99, 1359–1364.
Rolli, M., Fransvea, E., Pilch, J., Saven, A., and Felding-Habermann, B. (2003). Activated integrin alphavbeta3 cooperates with metalloproteinase MMP-9 in regulating migration of metastatic breast cancer cells. Proc. Natl. Acad. Sci. USA 100, 9482–9487.
Samani, A. A., Yakar, S., LeRoith, D., and Brodt, P. (2007). The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr. Rev 28, 20–47.
Scott, C. D., and Firth, S. M. (2004). The role of the M6P/IGF-II receptor in cancer: tumor suppression or garbage disposal? Horm. Metab. Res 36, 261–271.[CrossRef][Medline]
Smith, H. W., Marra, P., and Marshall, C. J. (2008). uPAR promotes formation of the p130Cas-Crk complex to activate Rac through DOCK180. J. Cell Biol 182, 777–790.
Tarui, T. et al. (2006). Direct interaction of the kringle domain of urokinase-type plasminogen activator (uPA) and integrin alpha v beta 3 induces signal transduction and enhances plasminogen activation. Thromb. Haemost 95, 524–534.[Medline]
Tarui, T., Majumdar, M., Miles, L. A., Ruf, W., and Takada, Y. (2002). Plasmin-induced migration of endothelial cells. A potential target for the anti-angiogenic action of angiostatin. J. Biol. Chem 277, 33564–33570.
van den Hoff, M. J., Moorman, A. F., and Lamers, W. H. (1992). Electroporation in ‘intracellular’ buffer increases cell survival. Nucleic Acids Res 20, 2902.
Wei, C. et al. (2008). Modification of kidney barrier function by the urokinase receptor. Nat. Med 14, 55–63.[CrossRef][Medline]
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
